MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

Inicio・Lista de Acciones・Cogent Biosciences Inc

Cogent Biosciences Inc

Cerrado

36.22 -0.36

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

35.39

Máximo

36.22

Métricas clave
By Trading Economics
Ingresos	-22M -102M
Empleados	258
EBITDA	-30M -109M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+44.69% upside

Dividendos
By Dow Jones
Próximas Ganancias	5 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	320M 5.9B
Apertura anterior	36.58
Cierre anterior	36.22

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

4.88 / 5.87 Soporte y Resistencia

Cogent Biosciences Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

16 abr 2026, 23:26 UTC

Acciones populares

Stocks to Watch: Netflix, Alcoa, Knight-Swift, NiSource

16 abr 2026, 20:41 UTC

Principales Movimientos del Mercado

Netflix Shares Slide After 2Q Outlook Misses Wall Street's Expectations

16 abr 2026, 23:49 UTC

Charlas de Mercado

Amplitude's Pivot to Oil-Linked Supply Deal Catches Bull's Eye -- Market Talk

16 abr 2026, 23:45 UTC

Charlas de Mercado

Nikkei May Decline After Hitting Record High -- Market Talk

16 abr 2026, 23:33 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Gold Edges Higher on Hopes for U.S.-Iran Deal -- Market Talk

16 abr 2026, 22:51 UTC

Charlas de Mercado

Netflix Sees Signs That Podcasts May Boost Engagement -- Market Talk

16 abr 2026, 22:08 UTC

Ganancias

Netflix Chair Reed Hastings to Leave Board in June -- 3rd Update

16 abr 2026, 22:06 UTC

Ganancias

Lundin Mining: Earnings From Discontinued Ops in 1Q Expected to Be Positively Impacted by Unaudited Gain on Disposal of Eagle Mine, Totaling Approximately $4M >LUN.T

16 abr 2026, 22:06 UTC

Ganancias

Lundin Mining: Pre-Announces Items Impacting 1Q Results

16 abr 2026, 22:06 UTC

Ganancias

Lundin Mining: Items of Significant Impact in 1Q Expected to Include Unaudited Realized Losses on Derivative Contracts of Approximately $13M, Primarily Related to Gold Collar Contracts >LUN.T

16 abr 2026, 22:06 UTC

Ganancias

Lundin Mining: Rev in 1Q Expected to Be Positively Impacted by Unaudited Provisional Pricing Adjustments on Prior-Period Concentrate Sales of Approximately $22M on Pre-Tax Basis >LUN.T

16 abr 2026, 22:06 UTC

Ganancias

Lundin Mining: Adjustments Primarily Include Upward Adjustments in Relation to Prior-Period Metal Sales >LUN.T

16 abr 2026, 20:50 UTC

Charlas de Mercado

Ganancias

Tech, Media & Telecom Roundup: Market Talk

16 abr 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

16 abr 2026, 20:50 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Basic Materials Roundup: Market Talk

16 abr 2026, 20:50 UTC

Charlas de Mercado

Ganancias

Health Care Roundup: Market Talk

16 abr 2026, 20:49 UTC

Ganancias

SpaceX Is Ready to Go Public. The Stock Market Is Its Rocket. -- Barrons.com

16 abr 2026, 20:43 UTC

Ganancias

Update: Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16 abr 2026, 20:40 UTC

Charlas de Mercado

Ganancias

Global Equities Roundup: Market Talk

16 abr 2026, 20:40 UTC

Charlas de Mercado

Ganancias

Netflix Says Engagement Quality Hits New High -- Market Talk

16 abr 2026, 20:30 UTC

Acciones populares

Stocks to Watch: TSMC, Abbott Laboratories, Nvidia, Netflix -- WSJ

16 abr 2026, 20:25 UTC

Ganancias

Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16 abr 2026, 20:23 UTC

Ganancias

These Stocks Are Today's Movers: AMD, Intel, TSMC, Abbott, Hims, Corning, Schwab, Polaris, and More -- Barrons.com

16 abr 2026, 20:19 UTC

Ganancias

Netflix Guidance Disappoints. The Stock Is Down. -- Barrons.com

16 abr 2026, 20:17 UTC

Ganancias

Alcoa: Alumina Costs in the Aluminum Segment Are Expected to Be Favorable by Approximately $20M Sequentially >AA

16 abr 2026, 20:17 UTC

Ganancias

Alcoa: Based on Higher LME and Midwest Premium Pricing and Expected Higher Shipments, Section 232 Tariff Costs on U.S. Imports of Aluminum From Canada Expected to Increase $35M Sequentially >AA

16 abr 2026, 20:16 UTC

Ganancias

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments Ranging Between 2.4M and 2.6M Metric Tons, and Between 2.6M and 2.8M Metric Tons, Respectively >AA

16 abr 2026, 20:16 UTC

Ganancias

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments to Remain Unchanged From Its Prior Projection >AA

16 abr 2026, 20:16 UTC

Ganancias

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments Ranging Between 9.7M to 9.9M Metric Tons, and Between 11.8M and 12.0M Metric Tons, Respectively >AA

16 abr 2026, 20:16 UTC

Ganancias

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments to Remain Unchanged From Prior Projection >AA

Comparación entre iguales

Cambio de precio

Cogent Biosciences Inc previsión

Precio Objetivo

By TipRanks

44.69% repunte

Estimación a 12 Meses

Media 52.55 USD 44.69%

Máximo 64 USD

Mínimo 35 USD

De acuerdo con 12 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Cogent Biosciences Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

12 ratings

Comprar

Mantener

Vender

De acuerdo con 12 analistas que ofrecen calificaciones bursátiles a para Cogent Biosciences Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

4.88 / 5.87Soporte y Resistencia

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.